Your browser doesn't support javascript.
loading
Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
Gulliver, Chloe; Huss, Sebastian; Semjonow, Axel; Baillie, George S; Hoffmann, Ralf.
Affiliation
  • Gulliver C; School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, G12 8TA, Scotland, UK. c.gulliver.1@research.gla.ac.uk.
  • Huss S; Gerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149, Münster, Germany.
  • Semjonow A; Prostate Center, University Hospital Münster, 48149, Münster, Germany.
  • Baillie GS; School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, G12 8TA, Scotland, UK.
  • Hoffmann R; School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, G12 8TA, Scotland, UK. ralf.hoffmann@philips.com.
Br J Cancer ; 129(9): 1462-1476, 2023 10.
Article in En | MEDLINE | ID: mdl-37740039
ABSTRACT

BACKGROUND:

Androgen signalling remains the seminal therapeutic approach for the management of advanced prostate cancer. However, most tumours eventually shift towards an aggressive phenotype, characterised by androgen independence and treatment resistance. The cyclic adenosine monophosphate (cAMP) pathway plays a crucial role in regulating various cellular processes, with the phosphodiesterase PDE4D7 being a vital modulator of cAMP signalling in prostate cancer cells.

METHODS:

Using shRNA-mediated PDE4D7 knockdown in LNCaP cells and downstream analysis via RNA sequencing and phenotypic assays, we replicate clinical observations that diminished PDE4D7 expression promotes an aggressive prostate cancer phenotype.

RESULTS:

Our study provides evidence that loss of PDE4D7 expression represents a pivotal switch driving the transition from an androgen-sensitive state to hormone unresponsiveness and neuroendocrine differentiation. In addition, we demonstrate that PDE4D7 loss affects DNA repair pathways, conferring resistance to poly ADP ribose polymerase (PARP) inhibitors.

CONCLUSION:

Reinstating PDE4D7 expression sensitises prostate cancer cells to anti-androgens, DNA damage response inhibitors, and cytotoxic therapies. These findings provide significant insight into the regulatory role of PDE4D7 in the development of lethal prostate cancer and the potential of its modulation as a novel therapeutic strategy.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Androgens Limits: Humans / Male Language: En Journal: Br J Cancer Year: 2023 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Androgens Limits: Humans / Male Language: En Journal: Br J Cancer Year: 2023 Document type: Article Affiliation country: United kingdom